Group 1 - The core point of the article highlights the significant stock price increase of Basestone Pharmaceuticals (02616), which rose over 9% in early trading and is currently at 7.29 HKD with a trading volume of 12.048 million HKD [1] - GIC has increased its stake in Basestone Pharmaceuticals to 6% as of October 13, marking its second substantial purchase in less than two months, having previously acquired 80.4 million shares for over 630 million HKD on August 18 [1] - The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sugli monoclonal antibody for the treatment of adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based chemoradiotherapy [1]
基石药业-B早盘涨超9% GIC时隔近两月再度增持公司股份 持股比例已达到6%